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Abstract Starting from the sequences of magainin 2 analogs, 
peptides with slightly increased hydrophobic moment (/x) but 
retained other structural parameters were designed. Circular 
dichroism investigations revealed that all peptides adopt an (X-
helical conformation when bound to phospholipid vesicles. 
Analogs with increased \i were considerably more active in 
permeabilizing vesicles mainly composed of zwitterionic lipid. In 
addition, the antibacterial and hemolytic activities of these 
analogs were enhanced. Correlation of permeabilization and 
binding indicated that the activity increase is predominantly 
caused by an increased membrane affinity of the peptides due to 
strengthened hydrophobic interactions. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
The potential to adopt an amphipathic a-helical conforma-
tion is a common structural feature of a multitude of mem-
brane-lytic cytotoxic and antimicrobial peptides. An amphi-
pathic conformation allows the peptides to incorporate into 
the membrane with the charged and polar amino acid side 
chains exposed to the lipid headgroups and the hydrophobic 
area embedded into the acyl chain region. After incorpora-
tion, the peptides enhance the permeability of membranes by 
different mechanisms such as pore formation or disruption of 
the integrity of the membrane (for review see [1,2]). Besides 
amphipathicity, other structural parameters such as overall 
hydrophobicity, peptide charge, position of charged residues 
and relative size of hydrophobic and hydrophilic cores are 
believed to influence peptide-membrane interaction [3-10]. 
Several structure function studies of natural peptide sequen-
ces and the de novo design of antimicrobial peptides revealed 
the general importance of amphipathicity, quantitatively ex-
pressed by the hydrophobic moment (|0.) [11], for membrane 
activity of helical peptides [4,7,12-16]. However, these inves-
tigations did not sufficiently consider that modifications of 
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peptide sequence generally alter more than one structural pa-
rameter capable of modulating membrane activity. For in-
stance, incorporation of bulky hydrophobic residues into the 
hydrophobic region of an amphipathic helix increases not 
only the hydrophobic moment (¡J,) but also the overall hydro-
phobicity. Likewise, incorporation of hydrophilic, positively 
charged amino acids in the polar region enhances the hydro-
philicity and the overall peptide charge in addition to \i. In 
such cases, it is impossible to assign the observed effect ex-
clusively to the alteration of u,. Consequently, there is a con-
siderable need of quantitative experimental data especially on 
the influence of small modifications of \i on membrane activ-
ity. 
To overcome the problem of complex changes of structural 
parameters due to peptide sequence modifications, we employ 
an approach of minimal sequence modification which allows 
the modification of one structural parameter while keeping the 
others largely constant [6,9]. Our recent investigation showed 
that slight modifications of structural parameters may sub-
stantially modify the antibacterial and hemolytic activities of 
amphipathic peptides [10]. In this work we investigated in 
detail the influence of \v on membrane activity and elucidated 
the biophysical principles providing the basis for the modu-
lation of membrane activity by \i. Starting from two analogs 
of the antibacterial frog peptide magainin 2, peptides with 
enhanced |i but retained hydrophobicity and number and po-
sitions of charged residues were synthesized. We studied the 
influence of \i on the helicity of the peptides and investigated 
the role of the interplay of ¡J. and membrane charge for the 
membrane-permeabilizing activity. Binding studies and their 
correlation with membrane permeabilization revealed the in-
fluence of \i on both steps of the membrane-permeabilizing 
process. 
2. Materials and methods 
2.1. Materials 
The lipids were purchased from Avanti Polar Lipids, Inc., Alabast-
er, AL, USA. The Fmoc amino acids were obtained from Novabio-
chem, Bad Soden, Germany. All other chemicals were of analytical or 
reagent grade. Peptides were synthesized by automated solid phase 
methods using Fmoc chemistry on a MilliGen 9050 peptide syn-
thesizer (Millipore, MA, USA) [17]. Tenta Gel S RAM resin (0.21 
mmol/g; RAPP Polymere, Tübingen, Germany) was used as the solid 
support. Purification was carried out by preparative HPLC to give 
final products > 95% pure by HPLC analysis. All peptides were char-
acterized by mass spectrometry (MALDI II; Kratos, Manchester, 
UK) and quantitative amino acid analysis (LC 3000, Biotronik-Ep-
pendorf, Germany). 
2.2. Vesicle preparation 
After vortexing the dried lipid in buffer (for CD: 10 mM Tris, 154 
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mM NaF, 0.1 mM EDTA, (pH 7.4), for calcein release: 10 mM Tris, 
70 mM calcein, 0.1 mM EDTA (pH 7.4)) small unilamellar vesicles 
(SUVs) were prepared by sonication (under nitrogen, in ice water) for 
25 min using a titanium tip ultrasonicator. Titanium debris was re-
moved by centrifugation. 
Calcein containing large unilamellar vesicles (LUVs) were prepared 
by the extrusion technique [18]: A lipid suspension (buffer: 70 mM 
calcein, 154 mM NaCl, 10 mM Tris, 0.1 mM EDTA, (pH 7.4)) was 
freeze-thawed in liquid nitrogen for seven cycles and extruded through 
polycarbonate filters (six times through two stacked 0.4 iim pore size 
filters followed by ten times through two stacked 0.1 urn pore size 
filters). Untrapped calcein was removed by gel filtration on a Sepha-
dex G75 column (eluent buffer: 10 mM Tris, 154 mM NaCl, 0.1 mM 
EDTA, (pH 7.4)). Lipid concentration was determined by phosphorus 
analysis [19]. 
2.3. Circular dichroism measurements 
CD measurements were carried out on a Jasco 720 spectrometer 
between 200 and 260 nm at 23°C. Minor contributions of circular 
dichroism and circular differential scattering by the SUVs were elim-
inated by subtracting the lipid spectra for the peptide-free suspension. 
The helicity of the peptides was calculated from the mean residue 
ellipticity at 222 nm [20]. 
CD-derived binding isotherms were determined from the changes of 
the CD of peptide solutions (three different concentrations between 
5X 10"5 M and 5X 10~6 M) after adding different amounts of SUVs. 
The theoretical principles of the method were described elsewhere [21]. 
2.4. Calcein release assay 
Aliquots of the vesicular suspension (10-20 |xl) were injected into a 
cuvette containing 2.5 ml of a stirred peptide solution at 23°C. Calcein 
release from vesicles was determined fluorometrically by measuring 
the decrease in self-quenching (excitation at 490 nm, emission at 
520 nm) on a Perkin-Elmer LS 50B spectrofluorometer. The fluores-
cence intensity corresponding to 100% release was determined by ad-
dition of Triton X-100 (100 ul, 10% v/v in water). 
2.5. Immobilized artificial membrane chromatography 
The retention behavior of the peptides was studied on an 
IAM.PC.DD column (100x4.6 mm i.d., particle size 5 um, 300 À, 
Regis Technologies, Inc., Morton Grove, IL, USA). Chromatographie 
measurements were performed on a Jasco gradient HPLC system 
(Jasco GmbH, Germany) consisting of two PU-980 pumps, an AS-
950 autoinjector, and a UV-975 detector operating at 220 nm. The 
sample concentration was 0.5 mg/ml of peptide in eluent A, and the 
injection volume was 20 ul. Runs were performed at 23°C (thermo-
stated system) and at an eluent flow rate of 0.8 ml/min. Mobile phases 
A and B consisted of 10 mM KH2PO4/K2HPO4, 154 mM NaCl in 
water, pH 7.4, and 10 mM KH2P04/K2HP04, 154 mM NaCl in 50% 
acetonitrile/50% water (v/v), pH 7.4, respectively. 
The isocratic retention times (ÍR) are used to calculate the capacity 
factors kjAu using the following equation: fciAm' = (lR~to)/to, where 
/R is the retention time of the peptide and t0 is the column void 
volume. A linear relationship exists between In /CIAM' and the organic 
mole fraction ty, according to In kyai = m ko'—S§, where S is a con-
stant and ko' is the capacity factor in absence of the organic solvent 
[22]. Hence, In ko' can be determined by linear regression analysis. 
The capacity factor ko' is linearly related to the equilibrium partition 
coefficient between lipid and aqueous phase according to fco' = yK, 
where \|/ is the phase ratio of the column. 
2.6. Hemolytic and antibacterial activity 
The hemolytic activity of the peptides was determined using human 
red blood cells as described previously [6]. In brief, the peptide con-
taining suspensions were incubated for 30 min at 37°C. After cooling 
in ice water and centrifugation an aliquot of the supernatant was 
mixed with 0.5% NH4OH and the optical density was measured at 
540 nm. Peptide concentrations causing 50% hemolysis (EC50) were 
derived from the dose-response curves. 
Antimicrobial susceptibility testing was performed using a modifi-
cation of the National Committee for Clinical Laboratory Standards 
(NCCLS) microdilution broth assay (1997). Mueller Hinton broth 
(BBL, Cockeysville, MD) was used for diluting the peptide stock 
solution and for dilution of the bacterial inoculum. The inoculum 
was prepared from mid-logarithmic phase cultures. The final concen-
tration of bacteria in the wells was 1-5 X 105 CFUs/ml. The final 
concentration of peptide solution ranged from 0.25 to 256 Ug/ml in 
2-fold dilution. Peptides were tested in duplicate. The microtiter plates 
were incubated overnight at 37°C and the absorbance was read at 630 
nm. The minimum inhibitory concentration (MIC) is defined as the 
lowest concentration of peptide that completely inhibits growth. 
3. Results 
3.1. Peptide design 
Peptides with enhanced hydrophobic moment (u) but hy-
drophobicities comparable to those of magainin 2 amide 
(M2a) or the more hydrophilic analog L 2 R n A 2 0 M2a were 
designed employing essentially the same principles as recently 
described for peptides with variations in the hydrophobicity 
[9]. Starting from the sequence of M2a up to 5 amino acids 
were substituted according to the following rules: (i) The 
number and positions of charged amino acids were unchanged 
to avoid modifications of interactions with charged membrane 
components, (ii) Amino acids in the hydrophilic region of the 
amphipathic helix were replaced by hydrophilic ones (H < 0, 
[11]), and residues in the hydrophobic region were substituted 
by hydrophobic amino acids ( H > 0 ) . Hence, the angles cir-
cumscribed by the hydrophobic and hydrophilic helix regions 
remained unchanged, (iii) The hydrophobicity of the analogs 
was adjusted to that of the parent peptides M2a or L 2 R U A 2 0 
M2a by appropriate, simultaneous substitutions in the hydro-
phobic and hydrophilic cores of the helix, (iv) The Gly resi-
dues were not substituted to avoid drastic changes in the 
helical propensity. 
The helical wheel presentations of the designed peptides as 
well as the biophysical data, based on the Eisenberg consensus 
scale of hydrophobicity [11], are given in Fig. 1. The first pair 
of peptides consists of L 2 R n A 2 0 M2a and I 6 R n R 1 4 W 1 6 M2a 
with hydrophobic moments of 0.287 and 0.332, respectively, 
and a constant hydrophobicity of —0.097 ±0 .001 . The second 
pair of peptides (M2a and i6v 9 W 1 2 T 1 5 I 1 7 M2a) is character-
ized by hydrophobic moments of 0.286 and 0.317, respec-
tively, and a higher hydrophobicity of —0.0355 ±0.0005. 
Table 1 
oc-helicity of the peptides in buffer, SDS and SUV suspensions 
Peptide Lipid/solvent 
Buffer SDS POPC SUVs POPC/POPG (3:1) SUVs POPG SUVs 
L 2 R 1 1 A 2 0 M 2 a 
[ 6 R 1 1 R 1 4 W 1 6 M 2 a 
VI2a 
[6V9W12T15I17 M2a 
0 
0 
0 
0 
55 
70 
68 
76 
18 
58 
51 
78 
56 
83 
76 
87 
58 
83 
77 
87 
Helical content was evaluated from [0]222 [20]. The peptide concentration was 50 uM in buffer (10 mM Tris, 154 mM NaF, 0.1 mM EDTA, (pH 
7.4)). The SDS concentration was 25 mM and the lipid concentration was 8.3 mM of POPG and POPC and 13 mM of POPC/POPG (3:1). 
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Fig. 1. Helical wheel projection of the parent peptides and the analogs with increased hydrophobic moment u. Black circles refer to charged or 
hydrophilic amino acids and white circles to hydrophobic residues. Hydrophobicity (H) and \i. were calculated using the consensus scale of hy-
drophobicity [11]. Both parameters are expressed as mean residue values throughout the paper. 
3.2. Conformational investigations 
The conformation of the peptides was investigated by CD 
spectroscopy in Tris-buffered saline, SDS solution and differ-
ent vesicle suspensions. All peptides adopted an unordered 
conformation in Tris-buffered saline (Table 1). In SDS solu-
tion as well as in the presence of negatively charged POPG 
and POPC/POPG (3:1) SUVs the peptides folded into mainly 
a-helical conformations. Interestingly, analogs with enhanced 
|i were more helical than the corresponding peptides with 
lower |x but the same hydrophobicity. Titration experiments 
with negatively charged vesicles revealed that, under the con-
ditions used, all peptides were completely membrane-bound 
(not shown). Thus, the differences in helicity in the presence 
of these vesicles reflect differences in the helicity of the lipid-
bound peptides. More pronounced differences in helicity were 
observed in the presence of zwitterionic POPC SUVs. How-
ever, not all the peptide was bound under these conditions 
and the large differences arose from both differences in the 
membrane affinity and differences in the helicity of the bound 
peptide. The strongly enhanced helicity of analogs with in-
creased (1 is an indication of their increased affinity to zwit-
terionic lipids. 
3.3. Permeabilization of vesicles and biological activity 
The ability of the peptides to permeabilize LUVs of differ-
ent surface charge (POPG, POPC/POPG (3:1), POPC) was 
tested by a dye release assay. The EC50 values of the initial 
rate of calcein release were used as a measure of the mem-
brane-permeabilizing activity (Table 2). All analogs were very 
effective and showed only slight differences in permeabilizing 
Table 2 
EC50 values of calcein release from LUVs, MIC values of antibacterial activity, EC50 values of hemolytic activity and capacity factors of pep-
tide retention on a IAM.PC.DD column 
Peptide Dye release EC50 (uM) Antibacterial activity MIC 
(ug/ml) 
Hemolysis EC50 
(uM) 
POPG LUVs POPC/POPG 
(3:1) LUVs 
POPC LUVs E. coli P. aeruginosa Human 
erythrocytes 
Capacity factor 
V 
IAM.PC.DD 
column 
L 2 R u A 20 M 2 a 0.16±0.01 
T 6R H R14 W 16 M 2 a 0.13 ±0.00 
M2a 0.18 ±0.01 
j6V9Wi2Ti5 l i7 M 2 a o.34±0.01 
7.45 ±0.05 
0.85 ±0.05 
1.2±0.1 
0.38 ±0.03 
65 ±1 
3.4 ±0.2 
5.8±0.2 
0.25 ±0.05 
256 
128 
128 
>256 
256 
256 
64 
>1000 
503 
428 
56 
240 
1980 
700 
3530 
EC50 values of dye release are the peptide concentrations inducing 50% dye release after 1 min. Values are the mean of two independent 
measurements ± error of the mean. The lipid concentration was 25 |J,M in buffer (10 mM Tris, 154 mM NaCl, 0.1 mM EDTA, (pH 7.4)). MIC 
is the minimum inhibitory concentration of bacterial growth and EC50 of hemolysis is the concentration of half-maximal lysis of human eryth-
rocytes. 
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Fig. 2. A: Binding isotherms of peptides on POPC/POPG (3:1) SUVs at 23°C. B: Dependence of calcein leakage from POPC/POPG (3:1) 
SUVs on total peptide concentration (cpeptide)- Calcein leakage is defined as the percent leakage after 30 min at a lipid concentration of 25 uM. 
The values are the mean of two independent measures ± error. C: Relationship between the percent calcein leakage and the molar ratio of 
bound peptide per lipid if). Symbols: L2RUA20 M2a (o), P^ 'R^W 1 6 M2a (D) M2a (•), l6v9W12T15I17 M2a (■). The r values corresponding 
to 50% release (r50%) were found to be 0.0118 ±0.0008 for L2RnA20 M2a, 0.0100 ±0.0013 for I6RnR14W16 M2a, 0.0098 ±0.0010 for M2a and 
0.0122 ±0.0016 for p^W^T1 5!1 7 M2a. The error of r50% was estimated from the error of the calcein leakage and the uncertainty of the bind-
ing isotherm. 
highly negatively charged POPG LUVs. In contrast, the abil-
ity of the analogs to permeabilize LUVs composed of zwitter-
ionic POPC was highly differentiated. An increase of |x of 
L 2 R n A 2o M 2 a f r o m o 287 to 0.332 (I6RnR1 4W1 6 M2a) re-
sulted in a 19-fold higher activity. Likewise, enhancement of \i 
of M2a from 0.286 to 0.317 (I6V9W12T15I17 M2a) increased 
the permeabilizing activity by a factor of about 23. The same 
relation between |x and permeabilizing activity was found at 
mixed POPC/POPG (3:1) LUVs. However, the differences 
between analogs of different \i were less pronounced for mixed 
vesicles. 
L 2RnA2 0 M2a and M2a were highly selective in permeabi-
lizing negatively charged (POPG) over zwitterionic mem-
branes (POPC). Enhancement of \i significantly increased ac-
tivity on POPC vesicles but scarcely influenced activity on 
POPG vesicles. In consequence, the selectivity of analogs 
with increased \i for negatively charged model membranes 
was reduced. 
The activity of the peptides on PC-rich model membranes 
correlated well with the antibacterial and hemolytic activity 
(Table 2). Increase of (j. for L2RnA2 0 M2a and M2a resulted 
in analogs with enhanced antibacterial and hemolytic activity 
(I6RnR1 4W1 6 M2a, I6V9W12T15I17 M2a). Increase of it for 
the native sequence (M2a->I6V9W12T15I17 M2a) did not re-
duce selectivity for E. coli over erythrocytes. However, the 
activity against P. aeruginosa was enhanced by a factor of 
four whereas the hemolytic activity was increased 8-fold, 
thus reflecting a slightly reduced antibacterial specificity. 
3.4. Binding investigations 
CD-derived binding isotherms of the peptides on POPC/ 
POPG (3:1) SUVs revealed a strongly enhanced lipid affinity 
for analogs with increased \i (Fig. 2A). In addition, the dye-
releasing activities of these analogs on POPC/POPG (3:1) 
SUVs were clearly higher than those of the corresponding 
peptides with a lower |j, (Fig. 2B). Binding of the peptides 
was correlated with the dose-response curves of dye release 
in order to calculate the ratios of bound peptide per lipid 
corresponding to a given release effect (Fig. 2C). The effi-
ciency of the bound peptide fraction to induce 50% dye release 
was only between 10 and 12 bound molecules per thousand 
lipid molecules showing little variability among all the ana-
logs. 
The binding of peptides to lipid was also investigated by 
immobilized artificial membrane chromatography on an 
IAM.PC.DD column. This column was recently developed 
to mimic the environment of phosphatidylcholine [23]. The 
capacity factor ko' of a peptide is linearly related to the par-
tition constant between aqueous and lipid phase, and can 
therefore be used as a measure for the lipid affinity of the 
peptide (Table 2). I6RnR1 4W1 6 M2a showed about an 8-
fold higher ko' value than the corresponding analog with a 
lower (J.. Likewise, the lipid affinity of I6V9W12T15I17 M2a was 
about 5-fold higher than that of M2a. 
4. Discussion 
The general importance of amphipathicity for antibacterial 
and hemolytic activity of helical peptides has long been rec-
ognized. Sixteen years ago, DeGrado et al. substituted resi-
dues 1 to 20 of melittin with a sequence capable of forming an 
idealized amphipathic oc-helix [12]. This led to a more hemo-
lytic peptide and impressively proved the effect of the amphi-
pathic helix on activity. More recently, there have been exten-
sive, successful studies directed to design basic amphipathic 
model peptides with lytic activity [3,13-15]. The role of am-
phipathicity has also been studied by strengthening or weak-
ening of helicity due to incorporation of helix-promoting or 
helix-destabilizing residues [6,24^27]. However, until now no 
studies have been devoted to quantitatively assess the influ-
ence of changes in the hydrophobic moment (u) on membrane 
activity and to exclude simultaneously the effect of variations 
of other structural parameters. 
In this work, we studied the impact of u. on membrane 
activity of magainin 2 analog peptides keeping overall charge 
and position of charged amino acids constant and hydropho-
bicities comparable to those of the parent peptides. 
CD investigations revealed that all peptides adopt an oe-
helical conformation in SDS solution as well as in the pres-
ence of phospholipid vesicles. Under the conditions used, the 
peptides were completely membrane-bound in POPG and 
POPC/POPG (3:1) SUV suspension. Lipid-bound M2a has 
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recently been reported to be helical over the entire peptide 
chain [28,29]. Because all analogs were derived from M2a 
by a few, conservative amino acid substitutions distributed 
over the whole peptide chain, we assume that differences in 
the helicities result from an overall stabilization or destabili-
zation of the helix rather than from an extension or short-
ening of the helical region. 
Lytic natural and model peptides comprise a large range of 
hydrophobic moment values, e.g. mastoparan: \i = 0.221; 
PGLa: |x = 0.260; bombolitin I: \i = 0.284; 5-hemolysin: 
|i = 0.380; model peptide Li5K7 [15]: ^ = 0.443; model peptide 
M2 [7]: n = 0.471; model peptide Hel9-9 [8]: n = 0.513. How-
ever, the peptides investigated in this study were characterized 
by comparatively small differences in \i (between 0.286 and 
0.332). Nevertheless, small increases of u, caused by few, con-
servative amino acid substitutions, were found to strongly 
enhance the permeabilizing activity on PC-rich LUVs as 
well as antibacterial and hemolytic activity (Table 2). Further-
more, the interplay of hydrophobicity and u\ is interesting to 
note : While a reduction of the hydrophobicity of M2a from 
-0.036 to -0.096 (L2RnA2 0 M2a) substantially decreased 
activity at PC-rich membranes, the activity could be com-
pletely restored, even at this low hydrophobicity, by enhanc-
ing n from 0.287 to 0.332 (I6RnR1 4W1 6 M2a). 
The finding that a slight increase of |0. may drastically en-
hance membrane activity, if other structural parameters are 
kept constant, may be useful for the design of more active 
antibacterial substances, but should also be considered when 
assessing the consequences of sequence modifications. Kiyota 
et al. [8] recently compared the membrane activity of amphi-
pathic model peptides with varying ratios of Leu to Lys. They 
discussed their results with regard to the hydrophobic-hydro-
philic balance assuming that all analogs had negligible differ-
ences in u, (|i was between 0.39 and 0.51). However, the results 
presented here clearly show that such differences in |x must not 
be neglected. 
Also, the influence of \i is often overcompensated by other 
effects and hence difficult to evaluate. Matsuzaki et al. did not 
find a correlation between |o. and lytic activity comparing mag-
ainin 2, alamethicin and melittin [30]. This is not surprising 
considering the large differences of other structural parame-
ters such as hydrophobicity and overall charge as well as the 
different modes of action of these peptides. However, the ab-
sence of a correlation between distantly related peptides does 
not exclude the possibility that the lytic activity of each of the 
peptides can be enhanced by an increase of its |0.. 
In contrast to their action on PC-rich vesicles, all peptides 
were almost equally potent in permeabilizing highly negatively 
charged POPG LUVs. Clearly, a correlation between biolog-
ical activity and permeabilization of POPG vesicles does not 
exist. In spite of this fact, comparison of peptide activity on 
membranes of different surface charge gives information 
about the role of electrostatic and hydrophobic interactions 
in the membrane permeabilization process. The differences in 
the permeabilizing activity between peptides of different (a. 
becomes more pronounced with decreasing content of nega-
tively charged lipid within the membrane (Table 2). Conse-
quently, the capability of \i to modulate membrane activity 
increased with decreasing electrostatic peptide-lipid interac-
tions and an increasing role of hydrophobic interactions. 
The enhanced membrane-permeabilizing activity of analogs 
with increased |x at PC-rich membranes can be caused by an 
increased membrane affinity or by an enhanced permeabilizing 
efficiency of the membrane-bound peptide fraction. The bind-
ing of the peptides to PC-rich membranes was investigated by 
CD spectroscopy on POPC/POPG (3:1) SUVs and by immo-
bilized artificial membrane chromatography (IAM.PC.DD, 
model for PC membranes). Both methods revealed an in-
creased lipid affinity for analogs with an enhanced n (Fig. 
2A, Table 2) and therefore a direct correlation between mem-
brane-permeabilizing activity and membrane affinity. In con-
trast, the permeabilizing efficiency of the membrane-bound 
peptide fraction showed little variability (Fig. 2C) and did 
not correlate with the overall membrane-permeabilizing effect 
(Fig. 2B). Consequently, the higher permeabilization activity 
of analogs with increased (i is mainly caused by an increased 
lipid affinity of these analogs. 
In summary, our results indicate that slight enhancement of 
|x by a few, conservative amino acid substitutions drastically 
increased membrane activity of magainin analog peptides. The 
activity increase was mainly caused by an increased binding of 
the peptides to the membrane due to increased hydrophobic 
interactions between lipid acyl chains and the hydrophobic 
helix core. 
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